Given the favorable prognostics of DDX43 hypomethylation which has been reported by the previous studies [9, 30, 37] and the association of this hypomethylation with R882H mutation in DNMT3A in our study, it may be concluded that R882H mutation may be a favorable prognostic factor for AML patients. This evidence concerns the gene DNMT3A and acute myeloid leukemia.